focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,753.00
Ask: 1,754.00
Change: -19.00 (-1.07%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 03rd Apr 2014 09:05

Associated British Foods: Citi increases target price from 2350p to 3000p, while its neutral rating remains unchanged.Booker Group: Investec shifts target price from 172p to 178p retaining a buy recommendation.BSkyB: HSBC Holdings moves target price from 600p to 610p, while keeping its underweight rating.Burberry: Deutsche Bank cuts target price from 1600p to 1575p maintaining its hold recommendation.CSR: N+1 Singer raises target price to 777p and reiterates its hold recommendation.Daily Mail & General Trust: Jefferies increases target price from 800p to 1016p and maintains a buy recommendation.Direct Line Group: Berenberg ups target price from 230p to 254p and keeps a hold recommendation.easyJet: JP Morgan raises target price from 1725p to 1965p and reiterates an overweight rating.First Group: JP Morgan lowers target price from 165p to 156p and keeps an overweight rating.Glaxo Smith Kline: JP Morgan reduces target price from 1750p to 1700p leaving its neutral rating unchanged.Greene King: JP Morgan lowers target price from 960p to 940p maintaining a neutral rating.Heritage Oil: UBS reduces target price from 325p to 300p, while its buy recommendation is kept.HSBC Holdings: Investec reduces target price from 745p to 640p and downgrades from buy to hold.Hyder Consulting: Investec upgrades from hold to buy with a target price of 510p.Ithaca Energy: Canaccord Genuity lowers target price from 180p to 175p, while its buy recommendation is kept.Lonmin: RBC Capital cuts target price from 370p to 360p and retains an outperform rating.Marston's: JP Morgan reduces target price from 180p to 155p staying with its neutral rating.McBride: Investec places both its target price (prev.: 120p) and its buy recommendation under review. Panmure Gordon cuts target price from 120p to 100p downgrading from buy to hold.Merlin Entertainment: Deutsche Bank raises target price from 395p to 430p and stays with its buy recommendation.Minoan Group: WH Ireland shifts target price from 20p to 28p and stays with its speculative buy recommendation.Mitchells & Butlers: JP Morgan increases target price from 460p to 530p upgrading to overweight.Parkmead Group: Westhouse Securities initiates with a target price of 400p and a buy recommendation.Pennon Group: UBS takes target price from 725p to 795p and reiterates a buy recommendation.Polymetal International: Citi lowers target price from 452p to 450p and stays with its sell recommendation.Resolution: Canaccord Genuity reduces target price from 375p to 300p maintaining a hold recommendation.Restaurant Group: JP Morgan shifts target price from 750p to 755p retaining an overweight rating.Rotork: RBC Capital initiates with a target price of 2800p and a neutral rating.Severn Trent: UBS takes target price from 1825p to 1885p leaving its neutral rating unaltered.Smith & Nephew: Numis downgrades from add to hold with a target price of 1000p.Spirax-Sarco Engineering: RBC Capital initiates with a target price of 3250p and an outperform rating.Tullow Oil: UBS cuts target price from 925p to 900p, while upgrading from neutral to buy.United Utilities: UBS ups target price from 750p to 775p keeping a neutral rating.Wincanton: Investec upgrades from hold to buy with a target price of 155p.
More News
Today 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
Today 08:49

GSK's depemokimab asthma treatment meets endpoints in latest trials

(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatment options for patients with severe asthma.

Read more
Today 07:21

GSK reports promising results from asthma treatment trials

(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.

Read more
20 May 2024 16:11

IN BRIEF: GSK executive buys GBP20,026 worth shares

GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares at 1,788 pence each. Worth total GBP20,026.

Read more
17 May 2024 17:38

London's FTSE nudges lower for week after record run

Haleon falls after GSK offloads remaining stake

*

Read more
17 May 2024 15:52

London close: Stocks recoup some earlier losses

(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.

Read more
17 May 2024 11:52

LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady

(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.

Read more
17 May 2024 09:03

TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion

(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.

Read more
17 May 2024 08:56

LONDON MARKET OPEN: FTSE 100 lacklustre as Wall Street rally ends

(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.

Read more
17 May 2024 08:39

GSK raises $1.5 bln from sale of remaining Haleon stake

May 17 (Reuters) - British drugmaker GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Haleon to institutional investors.

Read more
17 May 2024 07:42

LONDON BRIEFING: Land Securities ups dividend; GSK sells Haleon stake

(Alliance News) - Stocks in London are called to open lower, as investors wait for an inflation reading from the eurozone later this morning.

Read more
17 May 2024 07:29

GSK raises £1.25bn from sale of remaining Haleon stake

(Sharecast News) - GSK said on Friday that it has sold its remaining 4.2% stake in consumer health business Haleon, which it spun off in July 2022.

Read more
16 May 2024 17:33

FTSE 100 ends lower on disappointing corporate updates, BT Group soars

BT Group up after CEO aims for more than double free cash flow

*

Read more
16 May 2024 17:13

TOP NEWS: GSK to sell remaining holding in spin-off Haleon

(Alliance News) - GSK PLC on Thursday said it intends to sell its remaining stake in Haleon PLC, the consumer healthcare firm it spun out almost two years ago.

Read more
16 May 2024 17:02

GSK to sell entire 4.2% remaining stake in Haleon

(Sharecast News) - GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.